Hot Topics

Biotech

Biotech April 17, 2019

Feinstein stimulates talk of an arthritis breakthrough

By GREGORY ZELLER // An encouraging new study out of the Feinstein Institute for Medical Research says noninvasive bioelectronic stimulation – administered through the outer ear – can effectively reduce symptoms of rheumatoid arthritis. The potentially quantum leap for the treatment of RA and other inflammatory diseases was reported Tuesday in Bioelectronic Medicine, an open-access journal aggregating articles and data from across a dozen-plus basic and clinical disciplines, including biochemistry, neuroscience, bioengineering, artificial intelligence and…

Read More

Biotech July 24, 2018

For Applied DNA, ETCH Biotrace may be a pot of gold

By GREGORY ZELLER // Just six months after announcing a partnership to develop a new molecular-tracking system, a Long Island biotech and a Canadian medical-marijuana supplier are launching the world’s first cannabis tagging system. Stony Brook-based supply-chain, anti-counterfeiting, anti-theft and product-authentication specialist Applied DNA Sciences and Calgary-based pharmaceutical-solutions provider TheraCann International Benchmark Corp. on Tuesday announced the launch of ETCH Biotrace, which leverages Applied DNA’s CertainT platform to tag, test and track cannabis plants “in…

Biotech July 18, 2018

Nerve-stim startup Sanguistat shuffles its deck

By GREGORY ZELLER // A Connecticut-based biotech spun out of the Feinstein Institute for Medical Research has assembled a powerful collection of advisors and directors, including corporate heavyweights and recognized global leaders in the burgeoning field of biolelectronic medicine. Sanguistat Inc., a 2016 clinical-stage medical-device startup, has named Feinstein Institute President and CEO Kevin Tracey as chairman of its Scientific Advisory Board, a role that will leverage the pioneer’s decades of groundbreaking bioelectronics research. The…

Biotech July 12, 2018

In Applied DNA’s new UL partnership, it’s safety first

By GREGORY ZELLER // A new deal with a worldwide safe-sciences leader will expand a Long Island innovator’s already-impressive global reach. Illinois-based UL, known primarily as Underwriters Laboratories for most of its 124-year history, has reached a “commercial agreement” with Applied DNA Sciences that will “lay the foundation for a significant new development in product authentication and supply-chain traceability,” according to a statement from Applied DNA. Financial terms were not disclosed, but the partnership will…

Biotech June 20, 2018

At FSC, skin-deep startup joins Start-Up NY’s ranks

By GREGORY ZELLER // The Empire State Development Corp. has opened its books and welcomed another Long Island company into the Start-Up NY family. Farmingdale State College announced this week that startup biotech BF Innovation, which moved into FSC’s Broad Hollow Bioscience Park earlier this year, has been accepted into the Start-Up NY program, which boosts new and expanding businesses with tax breaks and innovative academic partnerships. BF Innovation plans to invest $1 million and…

Biotech June 6, 2018

Albany backs NYIT’s next-gen bioengineering lab

By GREGORY ZELLER // A new bioengineering laboratory is coming to the New York Institute of Technology’s Old Westbury campus, thanks to a hefty state award. The Empire State Development Corp. on Wednesday announced a $150,000 grant that will help NYIT establish the Bio-Nanotechnology and Biomaterials Laboratory, a research- and innovation-focused bioengineering lab packed with next-level tech facilitating specialized research into complex bioengineering, artificial-intelligence and life-sciences issues. The grant was awarded through Round 7 of…

Biotech June 5, 2018

SBU joins elite HHS business-development task force

By GREGORY ZELLER // Stony Brook University will join an elite roster of national institutions in a new business-development feeder system devised by the U.S. Department of Health & Human Services. Introduced Tuesday as a business-accelerator program under the auspices of BARDA, HHS’s Biomedical Advanced Research and Development Authority, the nationwide network will foster development of new “health security” protocols – that is, preparedness to respond to threats ranging from chemical attacks and radiological terrorism…